- 同
- purified chick embryo cell
WordNet
- immunogen consisting of a suspension of weakened or dead pathogenic cells injected in order to stimulate the production of antibodies (同)vaccinum
PrepTutorEJDIC
- 牛痘種,痘苗(牛痘を起こすビールスで,天然痘予防のために人体に接種される) / (伝染病の病原菌から作った)ワクチン
- Peace Corps 平和部隊
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Safety and immunogenicity study of a new purified chick embryo cell rabies vaccine Vaxirab-N (Pitman Moore strain) manufactured in India.
- Narayana DH, Shampur MN, Sampath G, Tripathy RM, Sudarshan MK, Bilugumbe G, Ravish HS, Satapathy DM, Gowda G, Holla R, Belludi AY, Padhi A, Shamanna M, Patel PM.Author information Department of Community Medicine; Kempegowda Institute of Medical Sciences (KIMS); Bangalore, India.AbstractZydus Cadila Health care, India developed a new purified chick embryo cell rabies vaccine (PCECV, Vaxirab-N; 1 mL) by adapting Pitman-Moore strain of virus on to the chick embryo fibroblast cell line in 2006. During 2007-10, a series of safety and immunogenicity studies were conducted as per ICH-GCP guidelines after obtaining permission from Drug Controller General of India. In the first study, Vaxirab-N was administered to 35 healthy adult volunteers by intramuscular (IM) route using pre exposure regimen. The geometric mean titer (GMT) of rabies virus neutralizing antibody (RvnAb) of 7.5 IU/mL on day 35. In the 2nd study, Vaxirab-N was administered to 35 healthy adult volunteers using simulated post- exposure prophylaxis regimen by IM route. A GMT of 6.3 IU/mL on day 14, 13.2 IU/mL on day 28 and 8.6 IU/mL on day 90 was obtained. In the 3rd study, Vaxirab-N administered by intradermal route using Updated Thai Red Cross (TRC) regimen in 36 healthy adult volunteers showed GMT of 7.8 IU/mL on day 14, 11.5 IU/mL on day 28 and 6.0 IU/mL on day 90. The 4th study was multi centric and Vaxirab-N was administered to 129 animal bite cases by IM route using post-exposure Essen regimen. The GMT following this schedule was 8.2 IU/mL on day 14, 13.01 IU/mL on day 28, 7.92 IU/mL on day 90 and 3.72 IU/mL on day 180. Mild to moderate adverse events were reported to Vaxirab-N but no serious adverse events were reported in any of these studies. In conclusion, Vaxirab-N developed by Zydus Cadila was found to be safe and immunogenic by both intramuscular and intradermal route and is recommended for rabies prophylaxis (CTRI No. 2010/091/000055 and 2010/091/000509).
- Human vaccines & immunotherapeutics.Hum Vaccin Immunother.2013 Sep 12;10(1). [Epub ahead of print]
- Zydus Cadila Health care, India developed a new purified chick embryo cell rabies vaccine (PCECV, Vaxirab-N; 1 mL) by adapting Pitman-Moore strain of virus on to the chick embryo fibroblast cell line in 2006. During 2007-10, a series of safety and immunogenicity studies were conducted as per ICH-GCP
- PMID 24030586
- Rabid fox bites and human rabies in a village community in southern India: epidemiological and laboratory investigations, management and follow-up.
- Madhusudana SN, Mani R, Ashwin YB, Desai A.Author information Department of Neurovirology, National Institute of Mental Health & Neurosciences (NIMHANS), and WHO Collaborating Centre for Reference and Research on Rabies, Bangalore, India. mshampur@hotmail.comAbstractHuman rabies transmitted from wild animals is rarely reported in endemic countries like India, where nearly 95% deaths occur due to bites from rabid dogs. In this paper, we report an incidence of rabid fox bites in a village in southern part of India involving 18 individuals, including 4 children. All people had category III exposures, including bites on the face and neck. The attacking fox was killed by the forest department and buried immediately. The victims of the fox bite did not receive appropriate and adequate postexposure treatment. Thirteen days after the bite, one of the bite victims developed typical symptoms of furious rabies and died 2 days later in a local hospital. His brain tissue, obtained at autopsy, was strongly positive for rabies by fluorescent antibody technique (FAT) and virus isolation. Panic prevailed in the community and the rest of the 17 cases were referred to our institute for advice and further management. Only 35% of them had protective levels of rabies virus neutralizing antibodies (RVNA). All of the patients were administered with an 8-site intradermal regimen with purified chick embryo cell (PCEC) vaccine and were followed up regularly. All of them developed adequate titers (>0.5 IU/mL) of RVNA 7 days later. They were under regular follow-up and after nearly 2 years none have developed rabies. The partial Nucleoprotein (N) gene sequencing of the virus isolate from the patient who died of rabies had close homology with species I (prototype rabies) sequences available in GenBank and our own past isolates from dogs and humans, thus confirming that virus spillover from wildlife to domestic dogs continues to occur. This episode should prompt health authorities to focus more attention on training rural medical practitioners in state-of-the-art modern prophylactic measures.
- Vector borne and zoonotic diseases (Larchmont, N.Y.).Vector Borne Zoonotic Dis.2013 May;13(5):324-9. doi: 10.1089/vbz.2012.1146. Epub 2013 Mar 8.
- Human rabies transmitted from wild animals is rarely reported in endemic countries like India, where nearly 95% deaths occur due to bites from rabid dogs. In this paper, we report an incidence of rabid fox bites in a village in southern part of India involving 18 individuals, including 4 children. A
- PMID 23473223
- Immunogenicity of intradermal vaccination of Japanese rabies vaccine for preexposure immunization following WHO recommendation.
- Yanagisawa N, Takayama N, Mannen K, Nakayama E, Suganuma A.Author information Department of Infectious Diseases, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. naokiy@cick.jpAbstractIn the present study, we evaluated the immunogenicity of intradermal vaccination of Japanese purified chick embryo cell rabies vaccine (PCEC-K) for preexposure immunization (PEI). A total of 39 healthy subjects were administered a single 0.1-ml dose of PCEC-K intradermally at the antebrachial region on days 0, 7, and 28. To assess immunogenicity, rabies neutralizing antibody (NA) titers were measured on days 7, 28, and 42 post vaccination. By day 42, all subjects developed NA titers ≥0.5 IU/ml (geometric mean titer, 2.7 IU/ml), a level that is considered protective. The vaccine was well tolerated; vaccinated subjects displayed minimal redness and pruritus. Although a 1.0-ml dose of PCEC-K administered subcutaneously is considered the standard method, the intradermal regimen using a 0.1-ml dose of PCEC-K is immunogenic, safe, and highly recommended for situations of vaccine shortage.
- Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.J Infect Chemother.2012 Feb;18(1):66-8. doi: 10.1007/s10156-011-0286-2. Epub 2011 Aug 2.
- In the present study, we evaluated the immunogenicity of intradermal vaccination of Japanese purified chick embryo cell rabies vaccine (PCEC-K) for preexposure immunization (PEI). A total of 39 healthy subjects were administered a single 0.1-ml dose of PCEC-K intradermally at the antebrachial region
- PMID 21809060
Japanese Journal
- 国産狂犬病ワクチンを用いたWHO方式による狂犬病曝露前免疫の検討
- 柳澤 如樹,高山 直秀,菅沼 明彦
- 感染症学雑誌 82(5), 441-444, 2008
- 本邦での狂犬病曝露前免疫は, 組織培養不活化ワクチン1回量1DmLを4週間隔で2回, その後6～12カ月後に1回皮下注射する方式が標準である. この方式では, 多くの渡航者にとって, 時間的な制約から3回の基礎免疫を完了することは極めて困難である.WHOでは曝露前免疫を行う方法として, 初回接種日を0日として, 0, 7, 28日に狂犬病ワクチンを接種することを推奨している (WHO方式). WH …
- NAID 130004331457
- 外国製狂犬病ワクチンに引き続き国産狂犬病ワクチンで狂犬病曝露後発病予防を受けた人々における抗狂犬病抗体価
- 高山 直秀,菅沼 明彦,笠井 大介,倉井 大輔
- 感染症学雑誌 76(10), 882-887, 2002
- … 当院のワクチン外来を受診した海外動物咬傷被害者での抗体検査の結果では, 外国でベロ細胞狂犬病ワクチン (PVRV) ないしニワトリ胚細胞狂犬病ワクチン (PCEC) の接種を受けて帰国した被害者に国産ワクチンを継続接種しても合計5回のワクチン接種後には発症防御に十分なレベルの抗体が産生されることが判明した. …
- NAID 130004330998
- 狂犬病ワクチン成分に対する過敏反応のため皮内接種法により狂犬病曝露前免疫を行った1例
- 高山 直秀,大隈 邦夫,作間 晋
- 感染症学雑誌 73(6), 600-601, 1999
- … In another hospital she was tested to find out whether she was allergic to the components of rabies vaccine (PCEC) manufactured by the Chemo-Sero-Theraptic Research Institute (Kaketsuken) by cutaneous reaction using a 2, 000-fold diluted PCEC. … In our clinic she was again examined by skin test using 0.1ml of 10-fold diluted PCEC. … Further we tested using 0.05ml and 0.1ml of non-diluted PCEC. …
- NAID 130004330786
Related Links
- Acronym Definition PCEC Purified Chick Embryo Cell Vaccine (Rabies Vaccine) PCEC Perth Convention and Exhibition Centre (Australia) PCEC Personal Certified Executive Chef PCEC Phillips Community Energy Cooperative (Green Institute Inc.)
- Journal of Biolo~ical Standardization (1984), 12, 29---46 A new inactivated tissue culture vaccine for use in man Evaluation of PCEC-vaccine by laboratory tests rabies R. Barth, Y H. Gruschkau, Y U. Bijok, t J. Hilfenhaus, t J ...
★リンクテーブル★
[★]